TAP accepts and reviews partnering inquiries year round.
TAP collaborates with and makes equity investments in biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations and orphan indications.
- Download and complete the TAP Inquiry Form
- Send the completed application and your non-confidential presentation to via email.
The approval process considers strategy, opportunities, and the potential for success.
NEED MORE INFO? Download this presentation (PDF) and a one-page information sheet (PDF).
Powerful value-added benefits of a TAP partnership
It starts with an equity investment in your company, but there are many other powerful value-added benefits that companies enjoy as part of a TAP partnership.
Currently, there are more than twenty clinical trials with TAP-supported therapies, including several registration-enabling clinical studies. But companies in the TAP portfolio have a higher probability of partnering with other companies or financial institutions. Being selected for the TAP Portfolio can have major benefits for companies—aside from helping to cure blood cancers, of course.
Strategy and diligence process
When determining who qualifies for inclusion in the TAP Portfolio, we consider many factors, including:
- Existing and emerging populations with high unmet needs
- Gaps in current and emerging treatment landscape
- Innovative science and first-in-class assets
- First-in-hematologyoncology and registration trials
Strong intellectual property, management, and finances are key factors in determining who is selected as a TAP partner.
Each year, TAP reviews opportunities from approximately 80–100 biotech companies to identify those with the highest potential to change the standard of care.
The rigorous TAP due diligence process includes five stages, including utilizing external experts (TAP Advisory Council) to assist with evaluation.
Funding only the most promising projects that have a clear path forward for patients, TAP only invests in several new projects annually, with an open partnering cycle all year long.
TAP Due Diligence Funnel (PDF)
TAP adds value to biotech companies beyond dollars
Why do companies want to be part of TAP?
Because of active collaboration with us, TAP portfolio companies benefit from Blood Cancer United's deep cancer insight, a key opinion leader (KOL) and clinical network, drug development, and business expertise.
The TAP record of success provides scientific & investment credibility as well as visibility, enabling companies to raise additional funds.
Testimonials
We are thrilled to partner with Blood Cancer United TAP in our shared mission to bring transformative therapies to blood cancer patients. Our partnership with Blood Cancer United enables us to leverage their extensive expertise in blood cancer research and patient advocacy, and to tap into their vast network of physicians, scientists, and patients to better inform us and to support our objective of developing novel, cutting edge therapies that improve patient outcomes.
Nicholas Siciliano, PhD
Chief Executive Officer of Vittoria Biotherapeutics
Being able to say that organizations like Blood Cancer United have done diligence on the scientific aspects of the company was very good for our credibility and it was reassuring to investors who were coming to the conversation without that scientific background.
Amanda Wagner
President and Chief Executive Officer, Immunitas Therapeutics
How did TAP impact the development of Elzonris®?
Blood Cancer United awarded several grants to Dr. Arthur Frankel between 1998-2008 to develop fusion protein therapies for blood cancers, including SL-401 (now known as Elzonris). TAP then partnered with Stemline Therapeutics in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Listen to what Dr. Arthur Frankel and Peter MacDonald, SVP of Corporate & Business Development of Stemline Therapeutics, have to say about Blood Cancer United, the role TAP played in the development of Elzonris and the value TAP created for Stemline beyond the funding amount.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.